While AI excels at screening vast compound libraries for potential drug candidates, it cannot overcome the ultimate bottleneck: the messy, complex, and poorly documented reality of human biology. The need for physical clinical trials remains the fundamental constraint on medical progress.

A critical disconnect exists in drug development: the decision to start a trial is most influenced by the number of academic publications on a target. However, this metric has no bearing on the trial's likelihood of success. The best predictor of success is actually strong human genetic evidence linking the target to the disease.

For CNS diseases, where animal models are notoriously unreliable predictors of efficacy, the most pragmatic R&D model is to quickly move promising new chemical entities into human trials. The focus shifts from extensive preclinical validation to early biological experimentation in humans for proof-of-concept.

The catastrophic failure rate in drug development isn't just bad luck; it's a structural problem. It originates from the very first decision: researchers, biased by existing literature and simplistic models, fixate on a single biochemical target, ignoring the body's complex, multi-faceted nature.

AI models trained on descriptive data (e.g., RNA-seq) can classify cell states but fail to predict how to transition a diseased cell to a healthy one. True progress requires generating massive "causal" datasets that show the effects of specific genetic perturbations.

Many promising biomarkers are merely correlated with a disease, not a cause. Developing effective drugs requires targeting mechanisms with a direct causal effect on the outcome. This distinction is so critical that Valo Health has a "Chief Causal AI Officer" role to emphasize the focus.

Despite the buzz, a clinical development expert cautions that AI's impact in drug development is limited. The primary bottleneck isn't the algorithms but the lack of sufficient, high-quality human biological data that can be translated into reliable predictions, as animal models often fail to provide it.

While AI is on the verge of cracking preclinical challenges, the biggest problem is the high drug failure rate in human trials. The next wave of innovation will use AI to design molecules for properties that predict human efficacy, addressing the fundamental reason drugs fail late-stage.

The bottleneck for AI in drug development isn't the sophistication of the models but the absence of large-scale, high-quality biological data sets. Without comprehensive data on how drugs interact within complex human systems, even the best AI models cannot make accurate predictions.